Atrial fibrillation (AF) is one of the most common types of cardiac arrhythmia, particularly among older adults. AF confers a 5-fold risk for thromboembolic stroke as well as a 2-fold higher risk for congestive heart failure, morbidity, and mortality. Although stroke remains an important and impactful complication of AF, recent studies have shown that AF is independently associated with other neurological disorders, including cognitive impairment and dementia, even after adjusting for prior ischemic stroke. We performed a review of the published literature on the association between AF and cognitive status. Further, we reviewed studies investigating the underlying mechanisms for this association and/or reporting the impact of AF treatment on cognitive function.
ability. 14 Multiple risk factors have been identified for dementia; however, age is one of the strongest risk factors for incident dementia.
The prevalence of dementia doubles every 5 years after the age of 65 . 15 The estimated worldwide number of people living with dementia was 36.5 million in 2010; this number is expected to more than triple to reach 115.4 million by 2050. 14 Vascular dementia is a subset of cognitive decline secondary to cerebrovascular events and represents nearly 20% of all dementia cases. 16 Interestingly, cerebrovascular risk factors have been shown to play a role not only in vascular dementia but also in other types of dementia such as Alzheimer's disease (AD) perhaps through promoting vascular oxidative stress and inflammation, which leads to altered cerebral blood flow (CBF) regulation, disruption of the blood brain barrier, and ultimately neuronal damage and worsening of coexisting neurodegenerative processes. 17, 18 Similar to AF, hypertension, diabetes mellitus, smoking, and coronary heart disease are vascular risk factors associated with dementia independent of stroke. 15, 19 In light of the fact that AF can be paroxysmal and minimally symptomatic, yet contribute to cerebral hypoperfusion and cerebral thromboembolism, it is plausible that AF contributes to subclinical events that lead to cognitive decline and dementia in older individuals and that treatment of AF might prevent or abrogate cognitive decline. Alternatively, because both AF and dementia are strongly associated with advancing age and share common risk factors, they may not have a direct pathophysiological connection. In this review, we searched for published studies examining: (1) independent associations between AF and cognitive decline or dementia, (2) mechanisms linking AF and cognitive decline or dementia, and (3) impact of AF treatments on cognitive decline or dementia.
ASSOCIATION OF ATRIAL FIBRILLATION AND DEMENTIA
In a population-based prospective cohort study of over 6,000 participants, Ott et al. reported a significant association of AF with all types of dementia (odds ratio, OR: 2.3) and cognitive impairment (OR:
1.7). 10 This association was independent of a prior history of strokes, which was rigorously adjudicated. Since Ott et al.'s seminal work, small observational studies have demonstrated independent associations between AF and incident dementia in patients with acute stroke. 20 Meielke et al., in a cohort study of 135 patients with incident dementia, reported that the participants with AF had a more rapid decline in cognition as measured by clinical dementia rating and mini-mental state examinations (MMSE) scores over a period of 3 years when compared to patients without AF. 21 These studies have prompted a closer assessment of the association between AF and dementia in larger prospective studies.
In one such study, a large prospective observational study including over 37,000 participants receiving care in a large community health care system (Intermountain Healthcare), Bunch et al. reported that a diagnosis AF was associated with 36% increased risk of incident dementia (as identified by International Classification of Diseases, Ninth Revision, codes from the electronic medical records) over a 5-year period after adjusting for age, sex, hypertension, hyperlipidemia, diabetes, renal failure, smoking, family history of dementia, myocardial infarction, previous stroke, heart failure, statin use, and antihypertensive mediation use. 3 through MMSE scores at baseline, penultimate, and 2-year follow-up visits. 22 Cognitive decline was defined as a drop of ≥ 3 points in the MMSE scores between visits, and incident dementia was defined as a score ≤ 23 points on follow-up visits. 22 The study found a similar association between history of AF and incident dementia (hazard ratio, HR:
1.4) after adjusting for multiple covariates.
Due to the variability in reports from various studies investigating the association of AF and cognitive decline or dementia, multiple meta-analyses have been performed to increase statistical power and resolve uncertainty. In 2011, Kwok et al. meta-analyzed the data from 15 prospective studies studying the association between AF and incident dementia (established through rigorous adjudication) with a total of 46,637 participants, and found that prevalent AF was associated with a significantly higher risk of dementia (OR: 2.0). 23 In another meta-analysis, Santangeli et al. reviewed 8 prospective observational studies with a total of 77,668 participants with no acute stroke and normal cognitive function at baseline who carried a diagnosis of AF at the time of enrollment. 24 They reported that AF was significantly and independently associated with increased rates of incident dementia (HR: 1.4, diagnosis of dementia made by either diagnosis codes or rigorous adjudication). 24 Similarly, Kalantarian et al.
performed a meta-analysis of 14 studies (5 cross-sectional, 9 prospective cohorts) with a total of 85,414 participants. 9 They reported that AF was associated with a higher risk of incident dementia (diagnosis of dementia established by either diagnosis codes or rigorous adjudication) in participants with history of prior strokes (relative risk, RR: 2.7), as well as those without prior history of stroke (RR: 1.4). 9 When viewed in aggregate, meta-analyses examining relations between AF and dementia suggest a strong and reproducible association between the 2 diseases, independent of history of stroke, and raise important questions about the potential mechanisms underlying this association.
POTENTIAL MECHANISMS UNDERLYING THE ASSOCIATION BETWEEN ATRIAL FIBRILLATION AND DEMENTIA

Cerebral Hypoperfusion
Cerebral hypoperfusion may explain the association between AF and dementia through 2 potential mechanisms: (1) beat-to-beat variability from AF resulting in frequent episodes of cerebral hypoperfusion 25 ;
and (2) overall reduced cardiac output from AF due to the lack of atrioventricular synchrony (Fig. 1) . [26] [27] [28] Due to the irregularly irregular nature of the cardiac rhythm in AF, it is plausible that beat-to-beat variability in cerebral perfusion might coexist during AF as compared to regular sinus rhythm. Given the lack reported an independent association between cardiac output (measured using cardiac magnetic resonance imaging) and incident dementia (adjusted-HR 1.66) and AD (adjusted-HR 1.65) at nearly 8 years of follow-up. 31 Of note, this analysis was not restricted to the participants with AF and included a population-based sample. The mechanisms linking reduced cardiac output and CBF to cognitive decline and AD have not been deciphered completely. Bell et al. proposed that cerebral hypoperfusion could contribute to the development of AD by impairing the clearance of amyloid-beta peptides across the brain blood barrier thus promoting its accumulation. 32 Yet, proof for this hypothesis is lacking, and it is important to note that human trials testing strategies aimed at reducing the brain amyloid burden to improve cognitive outcome have all failed calling for a better understanding of the impact of amyloid on cognitive outcome. 33, 34 Although these studies support the role of cerebral hypoperfusion mechanism for the observed association of AF and dementia, a substudy of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial argued against this mechanism. The study tested the cognitive status in 245 participants at baseline, at 2 months, and yearly after that. 35 No significant difference in the MMSE scores was observed between the rhythm-control and rate-control arms. 35 However, this study had a small sample size and these results have not been replicated in other studies. While cerebral hypoperfusion may be present, the mechanisms through which it exacts its effect on cognition remain to be elucidated. Furthermore, because of the conflicting nature of the results, alterative CBF unrelated mechanisms might play a more important role in affecting cognition.
Vascular Inflammation
Dementia and AF have both been linked to pathological vascular remodeling and are both pro-inflammatory states. [36] [37] [38] 40 As such, vascular inflammation has been proposed as a potential pathophysiological mechanism linking AF to dementia. [36] [37] [38] 40 In the Honolulu-Asia Aging Study, participants with an elevated Creactive protein (CRP) had a 3-fold higher risk for dementia. 36 Similar associations with incident dementia have been observed with CRP and another marker of systemic inflammation, interleukin (IL)-6 in the Rotterdam Study. 37 It has been suggested that Amyloid-plaques and neurofibrillary tangles in AD patients result from inflammation and damage to the blood-brain-barrier. AD has been strongly linked to upregulation in inflammatory markers such as IL-1, IL-6, and tumor necrosis factor-(TNF-). 38 Framingham Heart Study investigators did not find an independent association between circulating CRP or IL-6 and incident dementia over a mean follow-up of 7 years in 1,016 Framingham Heart Study participants. 39 However, in the same study, participants with higher spontaneous production of TNF-by peripheral blood mononuclear cells was associated with a risk of incident dementia. Thus, data are conflicting and do not definitely establish or refute the association of circulating inflammatory cytokines with dementia. However, majority of studies do support the association of inflammation (circulating markers as such as CRP and IL-6, other biomarkers (amyloid-beta peptides, Leptin, Clusterin, and apoliporotein), and/or spontaneous production of TNF-) with an increased risk of dementia. 40 Circulating inflammatory cytokines such as CRP and IL-6 have also been associated with incident AF. 41 In participants in the Cardiovascular Health Study, elevated CRP was independently associated with 24% increased risk of incident AF per standard deviation. 42 Likewise, in participants in the Framingham Heart Study, elevated osteoprotegerin (a TNF-receptor family member) was associated with an increased risk of incident AF. 43 It is still unclear whether inflammation is a cause or a consequence of AF. Frustaci et al. performed endomyocardial biopsies of the atrial septum in 12 patients and showed evidence of histopathological inflammation and fibrosis in patients with lone AF. 44 Thus, it is plausible that inflammation perpetuates the adverse atrial electrical and structural remodeling, and facilitates chronicity of AF. 45 Marcus et al. measured the gradient of CRP and IL-6 between the left atrium and coronary sinus in 46 patients with symptomatic AF undergoing catheter ablation. They reported that the median left atrial to coronary sinus gradient for CRP was significantly higher in patients who were in AF (positive number) at the time of blood collection as compared to those who were in sinus rhythm (negative number). Similar trend was observed in the levels of IL-6. Their observations suggest that presence of AF might stimulate inflammation rather than AF being a consequence of inflammation. 46 If AF is associated with the creation of a pro-inflammatory state, it appears possible that patients with AF are more susceptible to injury to the blood-brain barrier and deposition of amyloid, resulting in cognitive decline and progression of dementia. 47 These observations provide the impetus for further studies to determine the role of inflammation in mediating the association of AF with dementia, and test anti-inflammatory treatment strategies to reduce incidence and progression of cognitive decline in AF patients.
Cerebral Small Vessel Disease
Although cerebral infarction manifesting as a stroke is one of the most feared sequela of AF, subclinical cerebral ischemic lesions (as detected by magnetic resonance imaging [MRI]) have been reported in up to 90% of participants with AF. Although such subclinical lesions are often presumed to be caused by cerebral small vessel disease, the pathogenesis is not well understood and is likely multifactorial. 48, 49 Importantly, cerebral small vessel disease related lesions have been consistently associated with an increased rate of dementia and decline in global cognitive function. [50] [51] [52] Accordingly, small vessel disease associated brain pathology (such as lacunar infarcts, MRI-defined white matter hyperintensities, and cerebral microbleeds) may be a key mechanism linking AF to cognitive decline, even in the absence of overt strokes. Indeed, in a prospective study, Gaita et al. compared 180 subjects with history of AF (paroxysmal and persistent), but without history of stroke with 90 individuals in normal sinus rhythm. 53 Both groups underwent cognitive function testing and brain magnetic resonance imaging to determine the presence of MRI-defined white matter hyperintensities. 53 The study reported that 89% of individuals with paroxysmal AF and 92% of individuals with persistent AF had at least 1 area of WMH seen on MRI. 53 Chen et al. prospectively monitored cognitive status of 935 participants of the Atherosclerosis Risk Communities Study with no prior history of strokes or cognitive impairment. 4 They reported that over 10 years of follow-up, incident AF was associated with a greater annual average decline in digit symbol substitution and word fluency in patients with evidence of lacunar infarcts on MRI. 4 In contrast, incident AF was not associated with cognitive decline in patients without evidence of subclinical cerebral ischemia on MRI.
Similar to white matter hyperintensities and lacunar infarcts, cerebral microbleeds could also contribute towards the association of AF and dementia or cognitive decline. Cerebral microbleeds are small perivascular hemosiderin deposits that are best seen in the T2 gradient-recall echo and susceptibility-weighted MRI sequences as hypointensities (less than 10 mm in size). 48 Microbleeds have been observed in the elderly population, and in individuals with history of AD and prior strokes. 54 In the population-based Rotterdam scan study, the prevalence of microbleeds increased with age, from 6.5%
in patients aged 45-50 years to 37.5% in patients over 80 years of aged and approximately 15.3% of participants had at least 1 cerebral microbleed. 55 In addition, the presence of cardiovascular risk factors (hypertension, and smoking) in this study was also associated with increased risk of microbleeds. Although AF has not been independently associated with microbleeds, the 2 conditions share risk factors. 56 Furthermore, microbleeds create a great deal of controversy for treatment with anticoagulants in patients with AF because microbleeds have been associated with increased risk of incident intracranial hemorrhage (the most feared and devastating complication of the anticoagulation treatment). 57 Interestingly, the number of microbleeds in AF is directly related to future ischemic stroke risk. In a cross-sectional analysis of 550 participants with history of AF and ischemic stroke, Song et al. reported that increasing number of cerebral microbleeds was associated with higher CHADS2 and CHA2DS2-Vasc scores. 54 Furthermore, Von Norden et al. reported that the presence and number of cerebral microbleeds is associated with cognitive impairment in subjects with no history of dementia, independent of other coexisting small vessel disease related lesions. 58 Taken in sum, the literature supports the hypothesis that cerebral small vessel disease, and cerebrovascular ischemia or injury secondary to AF may contribute to the pathophysiology of dementia and cognitive decline.
Brain Atrophy
Multiple studies have reported the association of AF with loss of brain volume and cognitive impairment. In a cross-sectional study, Knecht et al. evaluated 122 subjects with history of AF but with no history of stroke in the German Competence Network on AF and compared them to 563 individuals with no prior history of AF or stroke in the same community. 59 The study found that hippocampal volume by MRI was significantly lower in the subjects with AF compared to participants without AF. Total brain volume and white matter hyperintensities were not significantly different between participants with AF and no AF. 59 Global cerebral volume has been associated with worse cognitive function in patients in dementia. 62 Thus, current evidence supports the role of global or regional brain volume loss as one of the potential mediators for the association of AF and dementia. The mechanism by which AF leads to cerebral volume loss, however, remains to be explored.
Shared Risk Factors Between Atrial Fibrillation and Cognitive Decline or Dementia
Associations between cognitive decline, dementia, and AF may relate to the fact that these processes share several cardiovascular risk factors that increase in prevalence with advancing age and include: hypertension, heart failure, diabetes mellitus, excessive alcohol intake, sleep disorders and other risk factors. [63] [64] [65] 74 Serum cytokines, and inflammatory markers were measured at 1, 3, 6, 9, and 12 months after randomization. In addition, participants underwent neurocognitive assessment at baseline and 1 year after enrollment in the study. 74 The authors reported that the levels of inflammatory markers (including CRP) and cytokines were significantly reduced in the atorvastatin/ ezetimibe group, compared to the placebo group.
Furthermore, the reduction in some of the inflammatory cytokines was also associated with improved neurocognitive function and lower volume loss of the left amygdala. 74 Although the data are sparse in this area, further study appears warranted to examine the potential benefits of statins to reduce vascular inflammation and cognitive decline among AF patients.
Catheter Ablation
Bunch et al. reviewed the medical records of 4,212 patients with AF who underwent catheter ablation in the Intermountain Healthcare hospitals and compared them to 16,848 age-and sex-matched patients with AF and no history of ablation, and 16,484 age-and sex-matched control patients without history of AF. The study found significantly lower rates of incident dementia among patients treated with catheter ablation when compared to no ablation over a 3-year follow-up. 75 The results from this study stand in contrast to the findings of Chung et al.
using data from a sub-study of the AFFIRM trial, which showed no significant difference in mini mental state examination scores between rate-and rhythm-control arms over a 3-year follow-up. 35 Future studies are warranted to understand the impact of rhythm restoration by catheter ablation or pharmacological approach on incidence and progression of dementia.
CONCLUSIONS AND FUTURE GOALS
Both AF and dementia share many risk factors. Although the prevalence of AF continues to increase likely due to ever-increasing aging population, 76 the prevalence of dementia has declined in the United
States over the last decade. 77 Multiple studies have proven the association of AF and dementia, independent of the history of stroke. A variety of mechanisms have been proposed to explain this relationship; however, larger studies investigating the impact of targeting the individual mechanisms have not been performed yet. Furthermore, to improve the rates of dementia detection in AF patients seen in the cardiovascular clinics, efficient risk stratifying and screening tools for dementia should be utilized. For example, since CHADS2 score is already utilized to estimate the risk of thromboembolism in AF, its association with dementia makes it a potential tool to risk stratify these patients for developing dementia. 67 
